Reactions 1704, p220 - 2 Jun 2018 Lenalidomide/pomalidomide/ thalidomide Deep vein thrombosis, pulmonary emboism and venous thromboembolism: 5 case reports In a study, 5 patients [ages not stated and not all sexes stated] were described, out of whom one man developed deep vein thrombosis (DVT) on pomalidomide, two patients developed venous thromboembolism (VTE) during treatment with thalidomide, and two patients developed VTE and pulmonary embolism (PE) or DVT during treatment with lenalidomide [routes, dosages and outcomes not stated]. Patient 1: The patient developed VTE complicated by pulmonary embolism during treatment with lenalidomide. The patient was started on lenalidomide for myeloma. Since cycle 3, the patient was commenced on aspirin as thromboembolism prophylaxis; however, the patient subsequently developed VTE complicated by pulmonary embolism at cycle 25. Patient 2: The patient developed VTE complicated by DVT during treatment with lenalidomide. The patient was started on lenalidomide for myeloma and enoxaparin sodium [enoxaparin] as thromboembolism prophylaxis. The patient discontinued enoxaparin sodium at cycle 6 and subsequently developed VTE complicated by DVT at cycle 9. Patient 3: The patient developed VTE during treatment with thalidomide. The patient was started on thalidomide for myeloma and aspirin as thromboembolism prophylaxis. At cycle 2, the patient developed VTE. Patient 4: The patient developed VTE during treatment with thalidomide. The patient was started on thalidomide for myeloma and enoxaparin sodium as thromboembolism prophylaxis. At cycle 2, the patient developed VTE. Patient 5: The man developed DVT during treatment with pomalidomide. The man was started on pomalidomide for myeloma and enoxaparin sodium as thromboembolism prophylaxis. At cycle 5, he switched prophylactic treatment to aspirin. During cycle 8, he developed DVT. Author comment: "Lenalidomide, thalidomide and pomalidomide are immunomodulatory drugs (IMiD’s) effective in the treatment of multiple myeloma which increase patient’s risk of venous thromboembolism." Melly M, et al. An audit of thromboprophylaxis for patients with myeloma on the immunomodulatory therapies: Thalidomide, lenalidomide or pomalidomide. British Journal of Haematology 181 (Suppl. 1): 186 abstr. BSH18-EP-055, Apr 2018. Available from: URL: http://doi.org/10.1111/bjh.15226 [abstract] - United Kingdom 803323785 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera